Results 41 to 50 of about 3,671,216 (244)

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

open access: yesFEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta   +3 more
wiley   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Low grade Gliomas Multi Modality Approach

open access: yesمجلة كلية الطب, 2009
Background: Gliomas are brain tumours of supporting tissue of the brain. The management of low grade glioma is still a great debate ranges from just follow up to extensive surgery followed by DXT, with or without chemothery.
Ali K. AL-Shalchy
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Feasibility of Laser Speckle-Based Perfusion Imaging in an Ex-Vivo Liver Model

open access: yesIEEE Journal of Translational Engineering in Health and Medicine
Objective: Advancing microcirculatory perfusion assessment methods is crucial for evaluating organ status during ex-vivo organ preservation and expanding the donor pool.
Ata Chizari   +10 more
doaj   +1 more source

MS-DCANet: A Novel Segmentation Network For Multi-Modality COVID-19 Medical Images

open access: yes, 2023
Xiaoyu Pan,1,* Huazheng Zhu,2,* Jinglong Du,1 Guangtao Hu,1 Baoru Han,1 Yuanyuan Jia1 1College of Medical Informatics, Chongqing Medical University, Chongqing, People’s Republic of China; 2College of Intelligent Technology and Engineering ...
Pan X, Han B, Hu G, Jia Y, Zhu H, Du J
core  

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Super phantoms: advanced models for testing medical imaging technologies

open access: yesCommunications Engineering
Phantoms are test objects used for initial testing and optimization of medical imaging techniques, but these rarely capture the complex properties of the tissue.
Srirang Manohar   +4 more
doaj   +1 more source

Robust Multi-Modality Person Re-identification

open access: yes, 2021
To avoid the illumination limitation in visible person re-identification (Re-ID) and the heterogeneous issue in cross-modality Re-ID, we propose to utilize complementary advantages of multiple modalities including visible (RGB), near infrared (NI) and ...
Chen, Zihan   +4 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy